{"id":"bethkis","safety":{"commonSideEffects":[{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Wheezing"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Bronchospasm"},{"rate":null,"effect":"Tinnitus"},{"rate":null,"effect":"Voice alteration"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:11:08.419083","_dailymed":{"setId":"1cd3d47b-025f-4705-9daf-cf07725ec223","title":"BETHKIS (TOBRAMYCIN) SOLUTION [CHIESI USA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tobramycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. The inhaled formulation allows high local concentrations in the respiratory tract while minimizing systemic exposure, making it particularly effective for treating chronic Pseudomonas aeruginosa lung infections in cystic fibrosis.","oneSentence":"Bethkis is an inhaled antibiotic that delivers tobramycin directly to the lungs to kill Pseudomonas aeruginosa bacteria in cystic fibrosis patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:06.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT06016088","phase":"PHASE1, PHASE2","title":"A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection","status":"RECRUITING","sponsor":"Respirion Pharmaceuticals Pty Ltd","startDate":"2024-04-01","conditions":"Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa","enrollment":72},{"nctId":"NCT01270347","phase":"PHASE3","title":"Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-01","conditions":"Cystic Fibrosis","enrollment":282},{"nctId":"NCT06262854","phase":"NA","title":"Efficacy and Safety of Stimulan® for the Treatment of Diabetic Foot Osteomyelitis. The BIG D-FOOT Study","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2024-03-01","conditions":"Diabete Mellitus, Foot Ulcer, Osteomyelitis - Foot","enrollment":50},{"nctId":"NCT04850313","phase":"NA","title":"Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2021-11-09","conditions":"Bacterial Corneal Ulcer","enrollment":3},{"nctId":"NCT02449031","phase":"","title":"Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-05-05","conditions":"Pseudomonas Aeruginosa in Cystic Fibrosis","enrollment":409},{"nctId":"NCT03502070","phase":"PHASE4","title":"Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2018-06-26","conditions":"Cystic Fibrosis","enrollment":47},{"nctId":"NCT03485456","phase":"PHASE1, PHASE2","title":"DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2019-05-29","conditions":"Cystic Fibrosis","enrollment":10},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03739528","phase":"PHASE3","title":"Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery","status":"COMPLETED","sponsor":"NTC srl","startDate":"2018-09-03","conditions":"Cataract","enrollment":808},{"nctId":"NCT01116089","phase":"PHASE1","title":"Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-07","conditions":"Cystic Fibrosis","enrollment":25},{"nctId":"NCT01111383","phase":"PHASE3","title":"A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-09","conditions":"Cystic Fibrosis","enrollment":209},{"nctId":"NCT01315678","phase":"PHASE3","title":"Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections","status":"COMPLETED","sponsor":"Insmed Incorporated","startDate":"2012-02-29","conditions":"Pseudomonas Aeruginosa Infection","enrollment":302},{"nctId":"NCT04122300","phase":"PHASE3","title":"Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct","status":"COMPLETED","sponsor":"University of Bern","startDate":"2011-05-22","conditions":"Congenita Nasolacrimal Duct Obstruction, Preterm Neonates, Ocular Discharge","enrollment":84},{"nctId":"NCT00885365","phase":"PHASE3","title":"A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-04","conditions":"Cystic Fibrosis","enrollment":324},{"nctId":"NCT03341741","phase":"PHASE3","title":"Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2014-03-11","conditions":"Cystic Fibrosis With Pulmonary Manifestations","enrollment":26},{"nctId":"NCT01456780","phase":"PHASE4","title":"Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-08","conditions":"Meibomian Gland Dysfunction, Posterior Blepharitis","enrollment":60},{"nctId":"NCT02207426","phase":"PHASE1","title":"Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™","status":"COMPLETED","sponsor":"Pharmaero ApS","startDate":"2014-07","conditions":"Healthy","enrollment":12},{"nctId":"NCT01844778","phase":"PHASE4","title":"Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-08","conditions":"Cystic Fibrosis","enrollment":60},{"nctId":"NCT01082367","phase":"PHASE3","title":"Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients","enrollment":50},{"nctId":"NCT02178540","phase":"PHASE4","title":"Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08","conditions":"Cystic Fibrosis","enrollment":45},{"nctId":"NCT01641822","phase":"PHASE3","title":"Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-12","conditions":"Cystic Fibrosis","enrollment":107},{"nctId":"NCT02734459","phase":"PHASE3","title":"A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery","status":"COMPLETED","sponsor":"Semler Research Center Pvt. Ltd.","startDate":"2013-11","conditions":"Bilateral Cataract","enrollment":756},{"nctId":"NCT00774072","phase":"PHASE2","title":"Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization","status":"COMPLETED","sponsor":"University of Jena","startDate":"2008-10","conditions":"Cystic Fibrosis, Pseudomonas Aeruginosa","enrollment":9},{"nctId":"NCT01938417","phase":"","title":"Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2006-10","conditions":"Orthopedic Operations","enrollment":12},{"nctId":"NCT01102244","phase":"PHASE3","title":"A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-04","conditions":"Blepharitis","enrollment":122},{"nctId":"NCT00362895","phase":"PHASE3","title":"A Bioequivalence Study of Tobradex AF","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-04","conditions":"Cataract","enrollment":995},{"nctId":"NCT01028027","phase":"PHASE3","title":"Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-10","conditions":"Conjunctivitis, Keratitis, Blepharitis","enrollment":357},{"nctId":"NCT00420628","phase":"PHASE4","title":"Pediatric Zylet Safety and Efficacy Study","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-11","conditions":"Chalazion, Hordeolum","enrollment":108},{"nctId":"NCT00834171","phase":"","title":"A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Ocular Hypertension","enrollment":50},{"nctId":"NCT01400750","phase":"PHASE4","title":"Comparison of 2 Treatment Regimens for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2001-08","conditions":"Cystic Fibrosis","enrollment":61},{"nctId":"NCT01337219","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® /Pulmoaid® in Patients With Cystic Fibrosis","status":"UNKNOWN","sponsor":"Erempharma","startDate":"2011-04","conditions":"Cystic Fibrosis","enrollment":36},{"nctId":"NCT01288170","phase":"NA","title":"Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®","status":"UNKNOWN","sponsor":"Erempharma","startDate":"2010-02","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT01227915","phase":"PHASE3","title":"Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2011-02","conditions":"Acute Bacterial Conjunctivitis","enrollment":70},{"nctId":"NCT00695435","phase":"PHASE1","title":"Tobramycin Tear Concentrations","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":"Dry Eye","enrollment":21},{"nctId":"NCT00399945","phase":"PHASE1","title":"Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT00420836","phase":"PHASE1","title":"Tobramycin Administered by eFlow Rapid Nebulizer: Pharmacokinetic Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-04","conditions":"Cystic Fibrosis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2006","pmid":"30000174","title":"Tobramycin.","journal":""},{"date":"2014 Jun 23","pmid":"24956309","title":"Tobramycin inhalation solution (Bethkis) for cystic fibrosis.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2014 Nov","pmid":"24464974","title":"Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis.","journal":"Pediatric pulmonology"},{"date":"2013 Sep","pmid":"24237172","title":"Inhaled antibiotics to treat lung infection.","journal":"Pharmaceutical patent analyst"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Bethkis®","genericName":"Bethkis®","companyName":"Mylan Inc.","companyId":"mylan-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bethkis is an inhaled antibiotic that delivers tobramycin directly to the lungs to kill Pseudomonas aeruginosa bacteria in cystic fibrosis patients. Used for Cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}